Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections

Hsin Yun Sun, Chien Yu Cheng, Chi Ying Lin, Chia Jui Yang, Nan Yao Lee, Bo Huang Liou, Hung Jen Tang, Yuang Meng Liu, Chun Yuan Lee, Tun Chieh Chen, Yi Chia Huang, Yuan Ti Lee, Ming Jui Tsai, Po Liang Lu, Hung Chin Tsai, Ning Chi Wang, Tung Che Hung, Shu Hsing Cheng, Chien Ching Hung

研究成果: Article同行評審

2 引文 斯高帕斯(Scopus)

摘要

BACKGROUND Hepatitis C virus (HCV) genotype 6 (HCV-6) infection is prevalent predominantly in Southeast Asia, and the data on the virologic response of HCV-6 to direct-acting antivirals (DAAs) are sparse in people living with human immunodeficiency virus (HIV) (PLWH). AIM To assess the virologic response of HCV-6 to DAAs in PLWH. METHODS From September 2016 to July 2019, PLWH coinfected with HCV-6 initiating DAAs were included. Laboratory investigations were performed at baseline, the end of treatment, and 12 wk off-therapy. RESULTS Of the 349 PLWH included (mean age 48.9 years, 82.5% men), 80.5% comprised people who inject drugs, 18.1% men who have sex with men, and 1.4% heterosexuals. Coexistent hepatitis B virus infection was present in 12.3% of the included PLWH, liver cirrhosis 10.9%, hepatocellular carcinoma 0.9%, and previous HCV treatment experience 10.9%. The mean baseline plasma HCV RNA was 6.2 log10 IU/mL. Treatment with glecaprevir/pibrentasvir was initiated in 51.9%, sofosbuvir/ledipasvir 41.5%, sofosbuvir/velpatasvir 6.3%, and sofosbuvir/daclatasvir 0.3%. At DAA initiation, antiretroviral therapy containing tenofovir alafenamide was given in 26.4%, tenofovir disoproxil fumarate 34.4%, non-tenofovir alafenamide/tenofovir disoproxil fumarate 39.3%, non-nucleoside reverse-transcriptase inhibitors 30.4%, protease inhibitors 4.0%, and integrase strand transfer inhibitors 66.8%; 94.8% of the included patients had CD4 counts ≥ 200 cells/mm3 and 96.0% had plasma HIV RNA < 50 copies/mL. Overall, 96.8% achieved undetectable plasma HCV RNA (< 30 IU/mL) at end of treatment; and 92.3% achieved sustained virologic response 12 wk off-therapy in the intention-to-treat analysis (93.5% in patients receiving sofosbuvir-based DAAs and 91.2% in those receiving glecaprevir/pibrentasvir). CONCLUSION Similar to the observation made in HIV-negative patients, sustained virologic response 12 wk offtherapy with DAAs is high in PLWH coinfected with HCV-6.

原文English
頁(從 - 到)1172-1183
頁數12
期刊World journal of gastroenterology
28
發行號11
DOIs
出版狀態Published - 2022 3月 21

All Science Journal Classification (ASJC) codes

  • 消化內科

指紋

深入研究「Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections」主題。共同形成了獨特的指紋。

引用此